Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.
Press releases published on April 24, 2025
Affini-T Therapeutics Presents Preclinical Data from its Programs Targeting Oncogenic Drivers KRAS and TP53 at AACR
EIN Presswire
·
April 24, 2025
BOSTON, MA, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- Affini-T Therapeutics to present data from pipeline programs targeting the cancer driver mutations KRAS G12V and TP53 R175H. Presentations will include real-world data on the low frequency …
Palisades Therapeutics Unveils Breakthrough Multi-Mechanistic Data for PT150 and PT157 in Resistant Cancers
EIN Presswire
·
April 24, 2025
Dual AR/GR Antagonism, Metabolic Reprogramming, and Lysosomal Bypass Position PT150 and PT157 as Best-in-Class Oncology Candidates CLIFFSIDE PARK, NJ, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- Pop Test Oncology LLC dba Palisades Therapeutics, …
Contraline Announces 24-Month Safety and Efficacy Results from First-in-Human Trial of ADAM™
EIN Presswire
·
April 24, 2025
CHARLOTTESVILLE, VA, UNITED STATES, April 24, 2025 /EINPresswire.com/ -- Contraline, a clinical-stage male contraception company, today announced that participants in the First-in-Human clinical trial of ADAM™ (“The ADAM Study”) have reached a critical …
Teknova to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, …
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire
·
April 24, 2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and …
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
GlobeNewswire
·
April 24, 2025
VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to …
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025
GlobeNewswire
·
April 24, 2025
MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8 …
Rapid Micro Biosystems to Announce First Quarter 2025 Financial Results on May 9, 2025
GlobeNewswire
·
April 24, 2025
LEXINGTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and …
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
GlobeNewswire
·
April 24, 2025
-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 -- -- CB-010 …
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
GlobeNewswire
·
April 24, 2025
TORONTO and HAIFA, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 24, 2025
Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a first installment of €130 million and (ii) the debt …
GENFIT : Résultats financiers annuels 2024 et point sur les activités de la Société
GlobeNewswire
·
April 24, 2025
Trésorerie et équivalents de trésorerie s’élevant à 81,8 millions d’euros au 31 décembre 2024. En outre, conclusion, en début d’année (i) d’un accord de royalty financing non dilutif d'un montant maximum de 185 millions d'euros comprenant un versement …
Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The …
Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to …
Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)
GlobeNewswire
·
April 24, 2025
GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
Treace to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities …
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it …
FluidForm Bio™ Announces Advance in Bioprinted Tissue Therapies with Landmark Publication in Science Advances
GlobeNewswire
·
April 24, 2025
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced the publication of a groundbreaking paper in the journal Science Advances detailing the development …
Seer to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
April 24, 2025
REDWOOD CITY, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2025 …
Merit Medical Reports First Quarter 2025 Results and Updates Full-Year Guidance
GlobeNewswire
·
April 24, 2025
First Quarter Highlights† Reported revenue of $355.4 million, up 9.8% Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectively GAAP operating margin of 11.5%, compared to 11.1% in prior year period Non-GAAP …